{"name":"Agendia","slug":"agendia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Dose dense AC followed by T + trastuzumab","genericName":"Dose dense AC followed by T + trastuzumab","slug":"dose-dense-ac-followed-by-t-trastuzumab","indication":"HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy)","status":"marketed"},{"name":"PTH followed by dose dense AC of FEC","genericName":"PTH followed by dose dense AC of FEC","slug":"pth-followed-by-dose-dense-ac-of-fec","indication":"HER2-positive early-stage breast cancer (neoadjuvant or adjuvant setting)","status":"marketed"},{"name":"TAC chemotherapy","genericName":"TAC chemotherapy","slug":"tac-chemotherapy","indication":"Breast cancer (neoadjuvant and adjuvant treatment)","status":"marketed"},{"name":"TC chemotherapy","genericName":"TC chemotherapy","slug":"tc-chemotherapy","indication":"Breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"},{"name":"TCH chemotherapy","genericName":"TCH chemotherapy","slug":"tch-chemotherapy","indication":"HER2-positive breast cancer (early-stage and metastatic)","status":"marketed"}]}],"pipeline":[{"name":"Dose dense AC followed by T + trastuzumab","genericName":"Dose dense AC followed by T + trastuzumab","slug":"dose-dense-ac-followed-by-t-trastuzumab","phase":"marketed","mechanism":"This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling.","indications":["HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy)"],"catalyst":""},{"name":"PTH followed by dose dense AC of FEC","genericName":"PTH followed by dose dense AC of FEC","slug":"pth-followed-by-dose-dense-ac-of-fec","phase":"marketed","mechanism":"This is a chemotherapy regimen combining paclitaxel/trastuzumab (PTH) followed by dose-dense doxorubicin/cyclophosphamide (AC) or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) to treat HER2-positive breast cancer.","indications":["HER2-positive early-stage breast cancer (neoadjuvant or adjuvant setting)"],"catalyst":""},{"name":"TAC chemotherapy","genericName":"TAC chemotherapy","slug":"tac-chemotherapy","phase":"marketed","mechanism":"TAC is a chemotherapy regimen combining docetaxel, doxorubicin, and cyclophosphamide to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.","indications":["Breast cancer (neoadjuvant and adjuvant treatment)","Node-positive breast cancer"],"catalyst":""},{"name":"TC chemotherapy","genericName":"TC chemotherapy","slug":"tc-chemotherapy","phase":"marketed","mechanism":"TC chemotherapy is a combination regimen of docetaxel (Taxotere) and cyclophosphamide that disrupts microtubule dynamics and cross-links DNA to kill rapidly dividing cancer cells.","indications":["Breast cancer (adjuvant and neoadjuvant treatment)","Non-small cell lung cancer"],"catalyst":""},{"name":"TCH chemotherapy","genericName":"TCH chemotherapy","slug":"tch-chemotherapy","phase":"marketed","mechanism":"TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors.","indications":["HER2-positive breast cancer (early-stage and metastatic)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOQllFSkRleFhPWnl2QXhPWmJfU3g5YXE4blowbk0wYWhwcUNzOUY0UkF1NnNUWENyVTZ1QmhjbjAtd3JXenVqQkZWUXo5NkxzRlY5aHlFcnNadzRjdUxnS0RsLXoxQTZ6UjJ2SDY1a0J1Wm9BaERaQy16M2w2b0lWLTB0X0NwWUxmdHFGU3NINjY?oc=5","date":"2026-04-01","type":"pipeline","source":"pharmaphorum","summary":"DNA testing can help right racial imbalance in breast cancer - pharmaphorum","headline":"DNA testing can help right racial imbalance in breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPM05oNEVUWTBER0Y0Ynh3UERpcWRIN0lIdHZBMHE1TlBlMm1xU2M0WWVOQlU3ZnlrSkVxc0VDbHpJeUs5dmlmOHNqcGVJQWhSLW5vZ0lqdU9CXzQ3VDBDYW91QzE0R0xKb1U3TFljQVhQcGQzZmVyQ2VramYwdjNJU0pjSk96MWU4cmk1MXM5X2FycmpQYmc0UkRRanlKX28xUDZzTi1lRFlHcmxlUGc?oc=5","date":"2026-03-11","type":"pipeline","source":"Medscape Reference","summary":"Adjuvant Targeted Therapies in High-Risk HR+/HER2- Early Breast Cancer - Medscape Reference","headline":"Adjuvant Targeted Therapies in High-Risk HR+/HER2- Early Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPWmxacTR3LUtBaEFrMWthem9HbWtPdGE0U19HSUk1ZFRqZDJmNkxFWnRhQ3RROWVoMGwzRTEwRWhVQmljdTE4N2N2NVhqdUFlMk9PcDF4c01GRDJLWVBvVXB6WGxDYXNZXzhwNzNONnNndk4yR2QzQjg3enFtMTFvdWJvYVhpa2ZCVWxpSy1iX3NKYlNfbWQxNHN2anZkMjA?oc=5","date":"2025-10-08","type":"pipeline","source":"Fierce Pharma","summary":"Galderma's Nemluvio itch relief claims scratched after Sanofi complaint - Fierce Pharma","headline":"Galderma's Nemluvio itch relief claims scratched after Sanofi complaint","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZjdyaUNqT19CamJOMUJfX0FwM00tdW5BRjBKMjdwRWdQb1JVemxTYmp2cjFHdVhwT0V4OHh2SDFtTXNCelVHVWxnWlNNTUxCa2duYlJqODh5NmNKalpGWUg3LXZ2Y0YyNS1JYjZIWkNRVFpaNTBNYTl2b2ViNGxWLUdyU2xscFlLZ0p2RENFT1RCbWVkZE9ManJ5aERzYmVaWEtpNy1MVXFhX2hXbEFYMG1iMXZVWmhDdVBXakR0U0trdw?oc=5","date":"2025-08-28","type":"pipeline","source":"Fierce Pharma","summary":"Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex - Fierce Pharma","headline":"Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZGQ3bXF4bWllZnNEZzR0U3c0ME1LQ3Z0NUFoUVd3VmRDaDhzYUJTLTBsSUtZbVVfZHg4SXlBTjZqNTRKRjlEMW9EU0RsU253OHBhZ0tQQkJCTGtPRWNOdndjZlVpTE5qQzlNaTZybmN5eWR0Ml9KTDNnQjFJOXNPMkJ6SElINk9XVk51Njh4dHpDVzhzT19XUFFiaG9nZUt6dnd0ZHZMRHVNb3JtZEEtX1FkWmlVSnJW?oc=5","date":"2025-08-13","type":"pipeline","source":"Fierce Pharma","summary":"Exact's Genomic Health puts rival Agendia in ad watchdog's crosshairs over LinkedIn posts - Fierce Pharma","headline":"Exact's Genomic Health puts rival Agendia in ad watchdog's crosshairs over LinkedIn posts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdjNESTZmUjFIc1pIYkN3VmNzVmZCZ1ZUZWM0bDdJUFlSS1VWQjg0dFB5VHFjbS04NVFMQUcwblc4QTlqMEZwdzFoanBhOWFwcFJSaXcxdzdRMzVndVFydUZLdFVMcGJxQjRROGJTcEw0WFVUd09Ra2xxbWVDeEtWZUxMMHZ6YmhERE1hZGQxMXVFUXBYelI1ZjJmQzJPQUs1OEUwczhiWlNUWndDa2V1Z1kzWncxbmN1OWxqcHpoaEIwajZEVXRfVDdFWW85elZ2VGhGQlB3?oc=5","date":"2022-01-10","type":"deal","source":"Via TT","summary":"Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care - Via TT","headline":"Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}